nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferoxamine—Growth retardation—Dactinomycin—melanoma	0.0405	0.0405	CcSEcCtD
Deferoxamine—Rash generalised—Vemurafenib—melanoma	0.0383	0.0383	CcSEcCtD
Deferoxamine—Tonic-clonic seizures—Carmustine—melanoma	0.032	0.032	CcSEcCtD
Deferoxamine—Induration—Bleomycin—melanoma	0.0221	0.0221	CcSEcCtD
Deferoxamine—Acute respiratory distress syndrome—Docetaxel—melanoma	0.0212	0.0212	CcSEcCtD
Deferoxamine—Lung infiltration—Bleomycin—melanoma	0.021	0.021	CcSEcCtD
Deferoxamine—Lung infiltration—Carmustine—melanoma	0.0184	0.0184	CcSEcCtD
Deferoxamine—Grand mal convulsion—Carmustine—melanoma	0.0181	0.0181	CcSEcCtD
Deferoxamine—Local reaction—Bleomycin—melanoma	0.0178	0.0178	CcSEcCtD
Deferoxamine—Transaminases increased—Carmustine—melanoma	0.0142	0.0142	CcSEcCtD
Deferoxamine—Visual acuity reduced—Temozolomide—melanoma	0.014	0.014	CcSEcCtD
Deferoxamine—Aphasia—Carmustine—melanoma	0.0133	0.0133	CcSEcCtD
Deferoxamine—Rash generalised—Docetaxel—melanoma	0.013	0.013	CcSEcCtD
Deferoxamine—Aphasia—Temozolomide—melanoma	0.0128	0.0128	CcSEcCtD
Deferoxamine—Scotoma—Carmustine—melanoma	0.0113	0.0113	CcSEcCtD
Deferoxamine—Scotoma—Temozolomide—melanoma	0.011	0.011	CcSEcCtD
Deferoxamine—Injection site pain—Carmustine—melanoma	0.0106	0.0106	CcSEcCtD
Deferoxamine—Eosinophilia—Vemurafenib—melanoma	0.0101	0.0101	CcSEcCtD
Deferoxamine—Infestation NOS—Vemurafenib—melanoma	0.00911	0.00911	CcSEcCtD
Deferoxamine—Infestation—Vemurafenib—melanoma	0.00911	0.00911	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Vemurafenib—melanoma	0.00893	0.00893	CcSEcCtD
Deferoxamine—Injection site reaction—Carmustine—melanoma	0.00856	0.00856	CcSEcCtD
Deferoxamine—Liver disorder—Docetaxel—melanoma	0.00812	0.00812	CcSEcCtD
Deferoxamine—Neuropathy—Carmustine—melanoma	0.00809	0.00809	CcSEcCtD
Deferoxamine—Connective tissue disorder—Vemurafenib—melanoma	0.00804	0.00804	CcSEcCtD
Deferoxamine—Neuropathy—Temozolomide—melanoma	0.00782	0.00782	CcSEcCtD
Deferoxamine—Eye disorder—Vemurafenib—melanoma	0.00764	0.00764	CcSEcCtD
Deferoxamine—Angiopathy—Vemurafenib—melanoma	0.00742	0.00742	CcSEcCtD
Deferoxamine—Mediastinal disorder—Vemurafenib—melanoma	0.00737	0.00737	CcSEcCtD
Deferoxamine—Scotoma—Docetaxel—melanoma	0.00729	0.00729	CcSEcCtD
Deferoxamine—Erythema—Vemurafenib—melanoma	0.00712	0.00712	CcSEcCtD
Deferoxamine—Swelling—Carmustine—melanoma	0.00709	0.00709	CcSEcCtD
Deferoxamine—Bone disorder—Docetaxel—melanoma	0.00613	0.00613	CcSEcCtD
Deferoxamine—Myalgia—Vemurafenib—melanoma	0.00606	0.00606	CcSEcCtD
Deferoxamine—Arthralgia—Vemurafenib—melanoma	0.00606	0.00606	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00602	0.00602	CcSEcCtD
Deferoxamine—Anaphylactic shock—Vemurafenib—melanoma	0.00581	0.00581	CcSEcCtD
Deferoxamine—Bone pain—Docetaxel—melanoma	0.00578	0.00578	CcSEcCtD
Deferoxamine—Infection—Vemurafenib—melanoma	0.00577	0.00577	CcSEcCtD
Deferoxamine—Nervous system disorder—Vemurafenib—melanoma	0.0057	0.0057	CcSEcCtD
Deferoxamine—Skin disorder—Vemurafenib—melanoma	0.00564	0.00564	CcSEcCtD
Deferoxamine—Injection site reaction—Docetaxel—melanoma	0.0055	0.0055	CcSEcCtD
Deferoxamine—Hypotension—Vemurafenib—melanoma	0.00543	0.00543	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00529	0.00529	CcSEcCtD
Deferoxamine—Neuropathy—Docetaxel—melanoma	0.0052	0.0052	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Vemurafenib—melanoma	0.00502	0.00502	CcSEcCtD
Deferoxamine—Dysuria—Temozolomide—melanoma	0.00488	0.00488	CcSEcCtD
Deferoxamine—Renal failure—Carmustine—melanoma	0.00474	0.00474	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Carmustine—melanoma	0.00472	0.00472	CcSEcCtD
Deferoxamine—Infestation—Temozolomide—melanoma	0.00466	0.00466	CcSEcCtD
Deferoxamine—Infestation NOS—Temozolomide—melanoma	0.00466	0.00466	CcSEcCtD
Deferoxamine—Body temperature increased—Vemurafenib—melanoma	0.00459	0.00459	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Temozolomide—melanoma	0.00456	0.00456	CcSEcCtD
Deferoxamine—Swelling—Docetaxel—melanoma	0.00455	0.00455	CcSEcCtD
Deferoxamine—Erythema—Bleomycin—melanoma	0.00431	0.00431	CcSEcCtD
Deferoxamine—Hallucination—Carmustine—melanoma	0.0043	0.0043	CcSEcCtD
Deferoxamine—Hypersensitivity—Vemurafenib—melanoma	0.00428	0.00428	CcSEcCtD
Deferoxamine—Connective tissue disorder—Carmustine—melanoma	0.00425	0.00425	CcSEcCtD
Deferoxamine—Visual disturbance—Docetaxel—melanoma	0.00424	0.00424	CcSEcCtD
Deferoxamine—Renal impairment—Docetaxel—melanoma	0.00422	0.00422	CcSEcCtD
Deferoxamine—Visual impairment—Carmustine—melanoma	0.00417	0.00417	CcSEcCtD
Deferoxamine—Hallucination—Temozolomide—melanoma	0.00416	0.00416	CcSEcCtD
Deferoxamine—Urinary tract disorder—Temozolomide—melanoma	0.00413	0.00413	CcSEcCtD
Deferoxamine—Pruritus—Vemurafenib—melanoma	0.00411	0.00411	CcSEcCtD
Deferoxamine—Connective tissue disorder—Temozolomide—melanoma	0.00411	0.00411	CcSEcCtD
Deferoxamine—Urethral disorder—Temozolomide—melanoma	0.0041	0.0041	CcSEcCtD
Deferoxamine—Eye disorder—Carmustine—melanoma	0.00404	0.00404	CcSEcCtD
Deferoxamine—Visual impairment—Temozolomide—melanoma	0.00403	0.00403	CcSEcCtD
Deferoxamine—Erythema—Dactinomycin—melanoma	0.00402	0.00402	CcSEcCtD
Deferoxamine—Diarrhoea—Vemurafenib—melanoma	0.00398	0.00398	CcSEcCtD
Deferoxamine—Eye disorder—Temozolomide—melanoma	0.00391	0.00391	CcSEcCtD
Deferoxamine—Tinnitus—Temozolomide—melanoma	0.0039	0.0039	CcSEcCtD
Deferoxamine—Arrhythmia—Carmustine—melanoma	0.00386	0.00386	CcSEcCtD
Deferoxamine—Leukopenia—Bleomycin—melanoma	0.00386	0.00386	CcSEcCtD
Deferoxamine—Dizziness—Vemurafenib—melanoma	0.00384	0.00384	CcSEcCtD
Deferoxamine—Angiopathy—Temozolomide—melanoma	0.00379	0.00379	CcSEcCtD
Deferoxamine—Immune system disorder—Temozolomide—melanoma	0.00378	0.00378	CcSEcCtD
Deferoxamine—Mediastinal disorder—Temozolomide—melanoma	0.00377	0.00377	CcSEcCtD
Deferoxamine—Erythema—Carmustine—melanoma	0.00377	0.00377	CcSEcCtD
Deferoxamine—Vomiting—Vemurafenib—melanoma	0.00369	0.00369	CcSEcCtD
Deferoxamine—Myalgia—Bleomycin—melanoma	0.00367	0.00367	CcSEcCtD
Deferoxamine—Headache—Vemurafenib—melanoma	0.00364	0.00364	CcSEcCtD
Deferoxamine—Erythema—Temozolomide—melanoma	0.00364	0.00364	CcSEcCtD
Deferoxamine—Leukopenia—Dactinomycin—melanoma	0.0036	0.0036	CcSEcCtD
Deferoxamine—Vision blurred—Carmustine—melanoma	0.00355	0.00355	CcSEcCtD
Deferoxamine—Oedema—Bleomycin—melanoma	0.00352	0.00352	CcSEcCtD
Deferoxamine—Anaphylactic shock—Bleomycin—melanoma	0.00352	0.00352	CcSEcCtD
Deferoxamine—Infection—Bleomycin—melanoma	0.0035	0.0035	CcSEcCtD
Deferoxamine—Nausea—Vemurafenib—melanoma	0.00345	0.00345	CcSEcCtD
Deferoxamine—Thrombocytopenia—Bleomycin—melanoma	0.00345	0.00345	CcSEcCtD
Deferoxamine—Vision blurred—Temozolomide—melanoma	0.00343	0.00343	CcSEcCtD
Deferoxamine—Myalgia—Dactinomycin—melanoma	0.00343	0.00343	CcSEcCtD
Deferoxamine—Leukopenia—Carmustine—melanoma	0.00337	0.00337	CcSEcCtD
Deferoxamine—Angioedema—Temozolomide—melanoma	0.00332	0.00332	CcSEcCtD
Deferoxamine—Hypotension—Bleomycin—melanoma	0.00329	0.00329	CcSEcCtD
Deferoxamine—Oedema—Dactinomycin—melanoma	0.00328	0.00328	CcSEcCtD
Deferoxamine—Convulsion—Carmustine—melanoma	0.00326	0.00326	CcSEcCtD
Deferoxamine—Infection—Dactinomycin—melanoma	0.00326	0.00326	CcSEcCtD
Deferoxamine—Leukopenia—Temozolomide—melanoma	0.00326	0.00326	CcSEcCtD
Deferoxamine—Thrombocytopenia—Dactinomycin—melanoma	0.00321	0.00321	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Bleomycin—melanoma	0.00321	0.00321	CcSEcCtD
Deferoxamine—Myalgia—Carmustine—melanoma	0.00321	0.00321	CcSEcCtD
Deferoxamine—Paraesthesia—Bleomycin—melanoma	0.00316	0.00316	CcSEcCtD
Deferoxamine—Convulsion—Temozolomide—melanoma	0.00315	0.00315	CcSEcCtD
Deferoxamine—Dyspnoea—Bleomycin—melanoma	0.00314	0.00314	CcSEcCtD
Deferoxamine—Myalgia—Temozolomide—melanoma	0.0031	0.0031	CcSEcCtD
Deferoxamine—Arthralgia—Temozolomide—melanoma	0.0031	0.0031	CcSEcCtD
Deferoxamine—Infestation NOS—Docetaxel—melanoma	0.0031	0.0031	CcSEcCtD
Deferoxamine—Infestation—Docetaxel—melanoma	0.0031	0.0031	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.00308	0.00308	CcSEcCtD
Deferoxamine—Oedema—Carmustine—melanoma	0.00307	0.00307	CcSEcCtD
Deferoxamine—Infection—Carmustine—melanoma	0.00305	0.00305	CcSEcCtD
Deferoxamine—Renal failure—Docetaxel—melanoma	0.00304	0.00304	CcSEcCtD
Deferoxamine—Neuropathy peripheral—Docetaxel—melanoma	0.00304	0.00304	CcSEcCtD
Deferoxamine—Pain—Bleomycin—melanoma	0.00301	0.00301	CcSEcCtD
Deferoxamine—Thrombocytopenia—Carmustine—melanoma	0.00301	0.00301	CcSEcCtD
Deferoxamine—Tachycardia—Carmustine—melanoma	0.003	0.003	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Dactinomycin—melanoma	0.00299	0.00299	CcSEcCtD
Deferoxamine—Anaphylactic shock—Temozolomide—melanoma	0.00297	0.00297	CcSEcCtD
Deferoxamine—Oedema—Temozolomide—melanoma	0.00297	0.00297	CcSEcCtD
Deferoxamine—Infection—Temozolomide—melanoma	0.00295	0.00295	CcSEcCtD
Deferoxamine—Nervous system disorder—Temozolomide—melanoma	0.00291	0.00291	CcSEcCtD
Deferoxamine—Thrombocytopenia—Temozolomide—melanoma	0.00291	0.00291	CcSEcCtD
Deferoxamine—Skin disorder—Temozolomide—melanoma	0.00288	0.00288	CcSEcCtD
Deferoxamine—Hypotension—Carmustine—melanoma	0.00287	0.00287	CcSEcCtD
Deferoxamine—Pain—Dactinomycin—melanoma	0.00281	0.00281	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Carmustine—melanoma	0.0028	0.0028	CcSEcCtD
Deferoxamine—Urticaria—Bleomycin—melanoma	0.0028	0.0028	CcSEcCtD
Deferoxamine—Body temperature increased—Bleomycin—melanoma	0.00278	0.00278	CcSEcCtD
Deferoxamine—Paraesthesia—Carmustine—melanoma	0.00276	0.00276	CcSEcCtD
Deferoxamine—Urinary tract disorder—Docetaxel—melanoma	0.00275	0.00275	CcSEcCtD
Deferoxamine—Dyspnoea—Carmustine—melanoma	0.00274	0.00274	CcSEcCtD
Deferoxamine—Connective tissue disorder—Docetaxel—melanoma	0.00273	0.00273	CcSEcCtD
Deferoxamine—Urethral disorder—Docetaxel—melanoma	0.00272	0.00272	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Temozolomide—melanoma	0.00271	0.00271	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Dactinomycin—melanoma	0.00268	0.00268	CcSEcCtD
Deferoxamine—Visual impairment—Docetaxel—melanoma	0.00268	0.00268	CcSEcCtD
Deferoxamine—Paraesthesia—Temozolomide—melanoma	0.00267	0.00267	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Carmustine—melanoma	0.00265	0.00265	CcSEcCtD
Deferoxamine—Dyspnoea—Temozolomide—melanoma	0.00265	0.00265	CcSEcCtD
Deferoxamine—Pain—Carmustine—melanoma	0.00263	0.00263	CcSEcCtD
Deferoxamine—Eye disorder—Docetaxel—melanoma	0.0026	0.0026	CcSEcCtD
Deferoxamine—Body temperature increased—Dactinomycin—melanoma	0.0026	0.0026	CcSEcCtD
Deferoxamine—Abdominal pain—Dactinomycin—melanoma	0.0026	0.0026	CcSEcCtD
Deferoxamine—Hypersensitivity—Bleomycin—melanoma	0.00259	0.00259	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Temozolomide—melanoma	0.00256	0.00256	CcSEcCtD
Deferoxamine—Pain—Temozolomide—melanoma	0.00254	0.00254	CcSEcCtD
Deferoxamine—Angiopathy—Docetaxel—melanoma	0.00252	0.00252	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Carmustine—melanoma	0.00251	0.00251	CcSEcCtD
Deferoxamine—Immune system disorder—Docetaxel—melanoma	0.00251	0.00251	CcSEcCtD
Deferoxamine—Mediastinal disorder—Docetaxel—melanoma	0.00251	0.00251	CcSEcCtD
Deferoxamine—Pruritus—Bleomycin—melanoma	0.00249	0.00249	CcSEcCtD
Deferoxamine—Arrhythmia—Docetaxel—melanoma	0.00248	0.00248	CcSEcCtD
Deferoxamine—Abdominal pain—Carmustine—melanoma	0.00243	0.00243	CcSEcCtD
Deferoxamine—Body temperature increased—Carmustine—melanoma	0.00243	0.00243	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Temozolomide—melanoma	0.00243	0.00243	CcSEcCtD
Deferoxamine—Erythema—Docetaxel—melanoma	0.00242	0.00242	CcSEcCtD
Deferoxamine—Hypersensitivity—Dactinomycin—melanoma	0.00242	0.00242	CcSEcCtD
Deferoxamine—Urticaria—Temozolomide—melanoma	0.00236	0.00236	CcSEcCtD
Deferoxamine—Abdominal pain—Temozolomide—melanoma	0.00235	0.00235	CcSEcCtD
Deferoxamine—Body temperature increased—Temozolomide—melanoma	0.00235	0.00235	CcSEcCtD
Deferoxamine—Muscle spasms—Docetaxel—melanoma	0.00233	0.00233	CcSEcCtD
Deferoxamine—Hypersensitivity—Carmustine—melanoma	0.00226	0.00226	CcSEcCtD
Deferoxamine—Diarrhoea—Dactinomycin—melanoma	0.00225	0.00225	CcSEcCtD
Deferoxamine—Vomiting—Bleomycin—melanoma	0.00224	0.00224	CcSEcCtD
Deferoxamine—Hypersensitivity—Temozolomide—melanoma	0.00219	0.00219	CcSEcCtD
Deferoxamine—Leukopenia—Docetaxel—melanoma	0.00217	0.00217	CcSEcCtD
Deferoxamine—Diarrhoea—Carmustine—melanoma	0.0021	0.0021	CcSEcCtD
Deferoxamine—Pruritus—Temozolomide—melanoma	0.0021	0.0021	CcSEcCtD
Deferoxamine—Convulsion—Docetaxel—melanoma	0.0021	0.0021	CcSEcCtD
Deferoxamine—Nausea—Bleomycin—melanoma	0.00209	0.00209	CcSEcCtD
Deferoxamine—Vomiting—Dactinomycin—melanoma	0.00209	0.00209	CcSEcCtD
Deferoxamine—Arthralgia—Docetaxel—melanoma	0.00206	0.00206	CcSEcCtD
Deferoxamine—Myalgia—Docetaxel—melanoma	0.00206	0.00206	CcSEcCtD
Deferoxamine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.00205	0.00205	CcSEcCtD
Deferoxamine—Dizziness—Carmustine—melanoma	0.00203	0.00203	CcSEcCtD
Deferoxamine—Diarrhoea—Temozolomide—melanoma	0.00203	0.00203	CcSEcCtD
Deferoxamine—Anaphylactic shock—Docetaxel—melanoma	0.00197	0.00197	CcSEcCtD
Deferoxamine—Oedema—Docetaxel—melanoma	0.00197	0.00197	CcSEcCtD
Deferoxamine—Dizziness—Temozolomide—melanoma	0.00196	0.00196	CcSEcCtD
Deferoxamine—Infection—Docetaxel—melanoma	0.00196	0.00196	CcSEcCtD
Deferoxamine—Vomiting—Carmustine—melanoma	0.00195	0.00195	CcSEcCtD
Deferoxamine—Nausea—Dactinomycin—melanoma	0.00195	0.00195	CcSEcCtD
Deferoxamine—Shock—Docetaxel—melanoma	0.00194	0.00194	CcSEcCtD
Deferoxamine—Nervous system disorder—Docetaxel—melanoma	0.00194	0.00194	CcSEcCtD
Deferoxamine—Thrombocytopenia—Docetaxel—melanoma	0.00193	0.00193	CcSEcCtD
Deferoxamine—Tachycardia—Docetaxel—melanoma	0.00193	0.00193	CcSEcCtD
Deferoxamine—Headache—Carmustine—melanoma	0.00193	0.00193	CcSEcCtD
Deferoxamine—Skin disorder—Docetaxel—melanoma	0.00192	0.00192	CcSEcCtD
Deferoxamine—Vomiting—Temozolomide—melanoma	0.00189	0.00189	CcSEcCtD
Deferoxamine—Headache—Temozolomide—melanoma	0.00186	0.00186	CcSEcCtD
Deferoxamine—Hypotension—Docetaxel—melanoma	0.00185	0.00185	CcSEcCtD
Deferoxamine—Nausea—Carmustine—melanoma	0.00183	0.00183	CcSEcCtD
Deferoxamine—Musculoskeletal discomfort—Docetaxel—melanoma	0.0018	0.0018	CcSEcCtD
Deferoxamine—Paraesthesia—Docetaxel—melanoma	0.00177	0.00177	CcSEcCtD
Deferoxamine—Nausea—Temozolomide—melanoma	0.00176	0.00176	CcSEcCtD
Deferoxamine—Dyspnoea—Docetaxel—melanoma	0.00176	0.00176	CcSEcCtD
Deferoxamine—Gastrointestinal disorder—Docetaxel—melanoma	0.00171	0.00171	CcSEcCtD
Deferoxamine—Pain—Docetaxel—melanoma	0.00169	0.00169	CcSEcCtD
Deferoxamine—Gastrointestinal pain—Docetaxel—melanoma	0.00161	0.00161	CcSEcCtD
Deferoxamine—Abdominal pain—Docetaxel—melanoma	0.00156	0.00156	CcSEcCtD
Deferoxamine—Body temperature increased—Docetaxel—melanoma	0.00156	0.00156	CcSEcCtD
Deferoxamine—Hypersensitivity—Docetaxel—melanoma	0.00146	0.00146	CcSEcCtD
Deferoxamine—Pruritus—Docetaxel—melanoma	0.0014	0.0014	CcSEcCtD
Deferoxamine—Diarrhoea—Docetaxel—melanoma	0.00135	0.00135	CcSEcCtD
Deferoxamine—Dizziness—Docetaxel—melanoma	0.00131	0.00131	CcSEcCtD
Deferoxamine—Vomiting—Docetaxel—melanoma	0.00126	0.00126	CcSEcCtD
Deferoxamine—Headache—Docetaxel—melanoma	0.00124	0.00124	CcSEcCtD
Deferoxamine—Nausea—Docetaxel—melanoma	0.00117	0.00117	CcSEcCtD
